follicular lymphoma (Cancer)
Information
- Disease name
- follicular lymphoma
- Disease ID
- DOID:0050873
- Description
- "A B-cell lymphoma that is characterized as an indolent non-Hodgkin's lymphoma and has_material_basis_in follicle center B-cells (centrocytes and centroblasts)." [url:http\://en.wikipedia.org/wiki/Follicular_lymphoma, url:http\://www.cancer.gov/dictionary?CdrID=428287]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03498612 | Active, not recruiting | Phase 2 | Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases | July 9, 2018 | April 30, 2026 |
| NCT04680052 | Active, not recruiting | Phase 3 | A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. | April 15, 2021 | August 9, 2028 |
| NCT04599634 | Active, not recruiting | Phase 1 | Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies | December 16, 2021 | February 8, 2027 |
| NCT04542824 | Active, not recruiting | Phase 1/Phase 2 | Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With R/R B-NHL | August 20, 2020 | December 30, 2024 |
| NCT03436602 | Active, not recruiting | Personalized Risk Stratification Model of Follicular Lymphoma Patients | March 1, 2018 | October 31, 2023 | |
| NCT03162536 | Active, not recruiting | Phase 1/Phase 2 | A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | June 26, 2017 | September 12, 2025 |
| NCT04962126 | Active, not recruiting | Phase 2 | Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy | August 17, 2021 | July 2025 |
| NCT03997968 | Active, not recruiting | Phase 1/Phase 2 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | October 9, 2019 | December 30, 2024 |
| NCT03078855 | Active, not recruiting | Phase 3 | A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma | September 7, 2017 | September 2024 |
| NCT03105336 | Active, not recruiting | Phase 2 | A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma | June 20, 2017 | January 2025 |
| NCT03884998 | Active, not recruiting | Phase 1 | Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma | February 26, 2019 | July 16, 2024 |
| NCT03245021 | Active, not recruiting | Phase 1 | Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A | September 7, 2017 | June 2027 |
| NCT03133221 | Active, not recruiting | Phase 2 | 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation | October 23, 2017 | March 2025 |
| NCT02722668 | Active, not recruiting | Phase 2 | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep | May 15, 2017 | December 2029 |
| NCT04246086 | Active, not recruiting | Phase 1/Phase 2 | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma | August 12, 2020 | November 15, 2027 |
| NCT00719888 | Active, not recruiting | Phase 2 | Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease | November 18, 2005 | December 22, 2024 |
| NCT04089215 | Active, not recruiting | Phase 2 | CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma | June 11, 2019 | September 30, 2024 |
| NCT03361852 | Active, not recruiting | Phase 1 | Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma | March 14, 2022 | December 26, 2033 |
| NCT03789240 | Active, not recruiting | Phase 2 | Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma | August 22, 2019 | January 1, 2027 |
| NCT02947347 | Active, not recruiting | Phase 3 | Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma | January 2017 | June 25, 2026 |
| NCT03636503 | Active, not recruiting | Phase 1 | RITUXIMAB + IMMUNOTHERAPY IN FOLLICULAR LYMPHOMA | October 30, 2018 | October 30, 2024 |
| NCT05387616 | Active, not recruiting | Phase 2 | A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden | October 19, 2020 | May 19, 2026 |
| NCT02315612 | Active, not recruiting | Phase 1 | Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies | December 12, 2014 | June 1, 2040 |
| NCT04082936 | Active, not recruiting | Phase 1/Phase 2 | A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma | September 30, 2019 | October 2024 |
| NCT02339922 | Active, not recruiting | Phase 2 | Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma | May 19, 2016 | January 6, 2031 |
| NCT01476787 | Active, not recruiting | Phase 3 | Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma | December 29, 2011 | April 30, 2024 |
| NCT02889523 | Active, not recruiting | Phase 1/Phase 2 | Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy | October 2016 | April 2026 |
| NCT06424379 | Active, not recruiting | BCL6-rearrangements Implications in Non-Hodgkin Lymphomas. | January 1, 2024 | June 30, 2025 | |
| NCT03600441 | Active, not recruiting | Phase 2 | Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma | August 27, 2018 | December 31, 2025 |
| NCT05784415 | Active, not recruiting | Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell | February 16, 2021 | August 31, 2025 | |
| NCT03568461 | Active, not recruiting | Phase 2 | Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma | November 12, 2018 | May 22, 2025 |
| NCT04806035 | Active, not recruiting | Phase 1 | Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia | April 23, 2021 | December 1, 2024 |
| NCT00487305 | Active, not recruiting | Phase 1 | Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma | June 2007 | October 2024 |
| NCT01650701 | Active, not recruiting | Phase 3 | A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma | February 2012 | April 2024 |
| NCT02631044 | Active, not recruiting | Phase 1 | Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) | January 6, 2016 | May 10, 2024 |
| NCT04018248 | Active, not recruiting | Phase 1 | BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I) | April 21, 2020 | March 2024 |
| NCT04750941 | Active, not recruiting | Phase 2 | Study of Copanlisib and Ketogenic Diet | February 10, 2022 | December 2024 |
| NCT05776160 | Available | Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel | |||
| NCT01306643 | Completed | Phase 1/Phase 2 | Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma | February 2011 | August 2015 |
| NCT04323657 | Completed | Phase 1/Phase 2 | TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia | March 27, 2020 | February 24, 2023 |
| NCT01314014 | Completed | Phase 2 | Imexon for Relapsed Follicular and Aggressive Lymphomas | May 2011 | August 2014 |
| NCT04160442 | Completed | N/A | Use of a Patient Preferences Shared Decision-Making Encounter Tool in Clinical Practice for Patients With DLBCL and FL | January 16, 2009 | June 30, 2020 |
| NCT01393756 | Completed | Phase 2 | Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma | December 2010 | November 2015 |
| NCT01419665 | Completed | Phase 3 | GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL) | December 1, 2011 | January 22, 2018 |
| NCT01446562 | Completed | Phase 2 | Y90 Ibritumomab Tiuxetan Post R-CHOP Chemotherapy for Advanced Stage Follicular Lymphoma | May 2007 | May 2016 |
| NCT01493479 | Completed | Phase 2 | Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma | June 6, 2007 | November 6, 2015 |
| NCT04034056 | Completed | Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN) | September 2, 2019 | April 22, 2024 | |
| NCT01523860 | Completed | Phase 2 | Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular Lymphoma | June 2009 | January 2015 |
| NCT01597778 | Completed | Phase 3 | Double Cord Versus Haploidentical (BMT CTN 1101) | June 2012 | September 11, 2020 |
| NCT01691898 | Completed | Phase 1/Phase 2 | A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) | September 27, 2012 | February 7, 2019 |
| NCT01760655 | Completed | Phase 2 | Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies | December 24, 2012 | December 5, 2022 |
| NCT01796171 | Completed | Phase 1/Phase 2 | A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma | December 2012 | October 27, 2022 |
| NCT03976102 | Completed | Phase 3 | Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma | May 15, 2019 | February 27, 2023 |
| NCT01926639 | Completed | Phase 2 | Phase II Cancer Vaccine Trial for Patients With Follicular Lymphoma | October 2009 | October 2014 |
| NCT01939899 | Completed | Phase 2 | Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma | October 31, 2013 | March 23, 2017 |
| NCT01953692 | Completed | Phase 1 | A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) | November 22, 2013 | June 26, 2020 |
| NCT00001572 | Completed | Phase 1 | Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype | January 30, 1997 | November 2, 2010 |
| NCT01980654 | Completed | Phase 2 | Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma | December 2013 | November 2017 |
| NCT02142530 | Completed | Phase 1 | Carfilzomib Plus Belinostat in Relapsed/Refractory NHL | October 2014 | January 2018 |
| NCT02187861 | Completed | Phase 2 | A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL) | December 1, 2014 | March 16, 2018 |
| NCT03833180 | Completed | Phase 1 | A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) | March 14, 2019 | December 18, 2023 |
| NCT02213263 | Completed | Phase 3 | A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06) | September 30, 2014 | April 19, 2018 |
| NCT02242045 | Completed | Phase 1 | Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL) | October 1, 2014 | October 17, 2017 |
| NCT03806179 | Completed | Phase 1 | Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL | October 4, 2018 | August 8, 2022 |
| NCT02260804 | Completed | Phase 3 | To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma | November 9, 2015 | September 4, 2019 |
| NCT02303119 | Completed | Phase 3 | Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT) | February 2, 2015 | June 29, 2021 |
| NCT02316613 | Completed | Prospective Observational Study on the Management of Patients With Relapsed or Refractory Follicular Lymphoma (OLYMPE) | February 2007 | April 2013 | |
| NCT02401048 | Completed | Phase 1/Phase 2 | A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas | May 2015 | November 2017 |
| NCT03610061 | Completed | Phase 1 | A Trial of Radiotherapy and Durvalumab in DLBCL and FL | November 1, 2018 | April 8, 2024 |
| NCT02461290 | Completed | Rituximab Therapy in Follicular Lymphoma in Combination With Chemotherapy - REFLECT 1 | April 2008 | November 2013 | |
| NCT02536664 | Completed | Non-Interventional Study to Examine Rituximab Treatment in Follicular Lymphoma Participants | September 2009 | June 2014 | |
| NCT03525665 | Completed | Study on the Role of FDG-PET in Patients With FL at Time of Relapse/Progression | May 2016 | December 30, 2019 | |
| NCT03520920 | Completed | Phase 2 | BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL) | January 4, 2018 | August 28, 2020 |
| NCT02661035 | Completed | Phase 2 | Allo HSCT Using RIC for Hematological Diseases | March 9, 2017 | May 29, 2023 |
| NCT02677155 | Completed | Phase 2 | Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma | January 2016 | February 2021 |
| NCT03381768 | Completed | Phase 1 | Peptide Vaccination Against PD-L1 and PD-L2 in Relapsed Follicular Lymphoma | December 12, 2017 | February 12, 2020 |
| NCT03128359 | Completed | Phase 2 | High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant | May 30, 2017 | September 15, 2021 |
| NCT00085696 | Completed | Phase 2 | VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma | May 2004 | |
| NCT00115700 | Completed | Phase 3 | Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma | February 2000 | August 2018 |
| NCT00140569 | Completed | Phase 3 | Randomized Study for Patients With Follicular Lymphoma Needing Treatment | January 1994 | January 2004 |
| NCT00140582 | Completed | Phase 3 | Primary Rituximab and Maintenance | December 2004 | December 2016 |
| NCT00169208 | Completed | Phase 2 | Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma | April 2001 | December 2006 |
| NCT00275431 | Completed | Phase 2 | Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies | November 2005 | December 2008 |
| NCT00366275 | Completed | Phase 2 | Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Relapsed or Refractory Follicular Lymphoma | January 2002 | September 2007 |
| NCT00393107 | Completed | Phase 2 | Safety and Efficacy of Fludarabine and Cyclophosphamide + Rituximab | March 2000 | August 2006 |
| NCT00406809 | Completed | Phase 1/Phase 2 | A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies | November 2006 | October 2016 |
| NCT00440388 | Completed | Phase 2 | Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma | October 2006 | November 2008 |
| NCT00513175 | Completed | Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia | October 2001 | November 2007 | |
| NCT00634179 | Completed | Phase 1/Phase 2 | A Phase I/II Trial of VR-CHOP in Lymphoma Patients | February 2008 | November 2015 |
| NCT00636792 | Completed | Phase 2 | A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma | February 2008 | May 2010 |
| NCT00644189 | Completed | Phase 1/Phase 2 | Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma | June 2008 | July 2021 |
| NCT00696735 | Completed | Phase 3 | High-Dose Therapy Treatment in Patients With Follicular Lymphoma | June 1994 | May 2006 |
| NCT00001512 | Completed | Phase 1 | Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines | September 9, 1996 | March 5, 2010 |
| NCT05064787 | Completed | N/A | Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy | March 11, 2022 | February 6, 2024 |
| NCT00783367 | Completed | Phase 2 | Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas | July 2008 | November 23, 2020 |
| NCT00794638 | Completed | Phase 1 | A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma | November 2008 | May 2010 |
| NCT00801281 | Completed | Phase 3 | First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. | February 2007 | June 25, 2017 |
| NCT00859001 | Completed | Phase 2 | Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy | ||
| NCT00880815 | Completed | Phase 1 | Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant | February 17, 2009 | May 28, 2019 |
| NCT00901615 | Completed | Phase 1/Phase 2 | Lenalidomide and R-CHOP in B-cell Lymphoma | January 6, 2009 | November 23, 2015 |
| NCT04918940 | Completed | N/A | Efficacy of COVID-19 Vaccination in Patientstreated With Anti-CD20 for Follicular Lymphoma or Mantle Cell Lymphoma | May 21, 2021 | June 27, 2022 |
| NCT04859920 | Completed | Living Conditions of Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma in the Côte d'Or Region | March 1, 2021 | April 30, 2021 | |
| NCT04858568 | Completed | Immune Responses to COVID-19 Vaccination in Lymphoma Patients | March 11, 2021 | January 31, 2024 | |
| NCT00992446 | Completed | Phase 2 | Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma | September 2, 2010 | October 29, 2019 |
| NCT01078142 | Completed | Phase 1/Phase 2 | Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma | February 2, 2010 | September 8, 2017 |
| NCT01109069 | Completed | Phase 2 | Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia | June 2010 | April 26, 2019 |
| NCT01118845 | Completed | Phase 2 | Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma | April 2010 | October 2011 |
| NCT01120457 | Completed | Phase 1 | First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers | August 2010 | November 2014 |
| NCT01130194 | Completed | Phase 2 | Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma | July 2006 | June 2012 |
| NCT01239394 | Completed | Phase 2 | Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma | December 2010 | March 2015 |
| NCT01275209 | Completed | Phase 1 | Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma | February 2011 | May 2012 |
| NCT01282424 | Completed | Phase 2 | Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas | March 18, 2011 | May 16, 2018 |
| NCT04508647 | Completed | Phase 2 | Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma | November 23, 2020 | July 14, 2022 |
| NCT03374137 | Completed | Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia | March 9, 2018 | November 10, 2022 | |
| NCT02877550 | Completed | Phase 1 | Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients | February 15, 2017 | May 4, 2022 |
| NCT03329950 | Completed | Phase 1 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | December 1, 2017 | September 13, 2022 |
| NCT03297424 | Completed | Phase 1 | A Study of PLX2853 in Advanced Malignancies. | September 12, 2017 | June 7, 2021 |
| NCT02978898 | Completed | CD180 Overexpression in Follicular Lymphoma | June 2012 | June 2015 | |
| NCT03276468 | Completed | Phase 2 | Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas | February 12, 2018 | August 24, 2022 |
| NCT03010982 | Completed | Phase 1 | Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors | June 20, 2018 | January 8, 2019 |
| NCT03019666 | Completed | Phase 1 | Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL | October 18, 2017 | August 15, 2022 |
| NCT03069248 | Completed | Phase 2 | Treatment of Follicular Lymphoma With High Dose Therapy and Stem Cell Support Followed by Rituximab and Alpha Interferon | June 1, 2000 | September 17, 2009 |
| NCT02756247 | Completed | Phase 1 | A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma | May 9, 2016 | October 6, 2022 |
| NCT03424603 | Completed | Phase 1 | Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies | February 22, 2018 | March 15, 2024 |
| NCT03113422 | Completed | Phase 2 | Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy | December 27, 2017 | January 6, 2023 |
| NCT01804686 | Enrolling by invitation | Phase 3 | A Long-term Extension Study of PCI-32765 (Ibrutinib) | September 9, 2013 | January 29, 2027 |
| NCT06049485 | Not yet recruiting | Assessing the Experience of Patients Undergoing Follicular Lymphoma Clinical Research | October 2024 | October 2026 | |
| NCT05990465 | Not yet recruiting | Phase 1 | LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies | July 2024 | July 2027 |
| NCT06368167 | Not yet recruiting | Phase 2 | A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma | April 2024 | April 2027 |
| NCT06142188 | Not yet recruiting | Relmacabtagene Autoleucel in Hematologic Malignancies | December 28, 2023 | December 31, 2038 | |
| NCT05749549 | Not yet recruiting | Phase 1/Phase 2 | Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers | April 2023 | May 2026 |
| NCT06068881 | Not yet recruiting | Phase 2 | A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation | September 2, 2024 | September 28, 2027 |
| NCT02194751 | Not yet recruiting | Phase 2 | Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma | July 2021 | June 2026 |
| NCT05923502 | Not yet recruiting | (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL) | October 20, 2023 | November 30, 2027 | |
| NCT05643742 | Recruiting | Phase 1/Phase 2 | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies | March 10, 2023 | February 2030 |
| NCT01962636 | Recruiting | N/A | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases | December 2016 | October 2025 |
| NCT02449252 | Recruiting | Phase 3 | Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Follicular Lymphoma | October 2015 | October 2025 |
| NCT03190928 | Recruiting | Clonal Evolution in Follicular Lymphoma | July 27, 2017 | January 1, 2029 | |
| NCT03314974 | Recruiting | Phase 2 | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | March 30, 2018 | November 10, 2025 |
| NCT03375619 | Recruiting | Long-term Follow-up Study of Patients Receiving CAR-T Cells | December 1, 2017 | January 1, 2035 | |
| NCT03452774 | Recruiting | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | January 1, 2018 | June 2027 | |
| NCT03501576 | Recruiting | Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma | April 6, 2018 | October 22, 2024 | |
| NCT03622788 | Recruiting | Phase 1/Phase 2 | Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant | August 8, 2019 | December 1, 2025 |
| NCT03676504 | Recruiting | Phase 1/Phase 2 | Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR | September 7, 2018 | April 1, 2024 |
| NCT03842696 | Recruiting | Phase 1/Phase 2 | Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation | February 4, 2020 | June 30, 2026 |
| NCT03980171 | Recruiting | Phase 1/Phase 2 | Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma | August 19, 2019 | November 2026 |
| NCT04072458 | Recruiting | Phase 1 | A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies | November 5, 2020 | January 2026 |
| NCT04186520 | Recruiting | Phase 1/Phase 2 | CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies | May 18, 2020 | January 2025 |
| NCT04223765 | Recruiting | Phase 1 | Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. | November 12, 2020 | March 22, 2043 |
| NCT04224493 | Recruiting | Phase 3 | Study of Tazemetostat Versus Placebo When Given in Combination With Lenalidomide and Rituximab in Participants With Relapsed/Refractory Follicular Lymphoma | June 11, 2020 | March 1, 2029 |
| NCT04282018 | Recruiting | Phase 1/Phase 2 | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | May 25, 2020 | December 31, 2025 |
| NCT04305444 | Recruiting | Phase 2 | Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas | April 24, 2020 | March 2024 |
| NCT04468841 | Recruiting | Phase 1 | Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma | July 8, 2020 | July 2024 |
| NCT04491370 | Recruiting | Phase 1/Phase 2 | Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma | August 1, 2021 | August 15, 2025 |
| NCT04545762 | Recruiting | Phase 1 | Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma | September 11, 2020 | October 31, 2024 |
| NCT04587388 | Recruiting | Towards Personalized Medicine for Refractory/Relapsed Follicular Lymphoma Patients: the Cantera/Lupiae Registry | May 22, 2019 | May 22, 2026 | |
| NCT04594642 | Recruiting | Phase 1 | A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | March 2, 2021 | January 15, 2027 |
| NCT04663347 | Recruiting | Phase 1/Phase 2 | Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) | November 3, 2020 | March 31, 2029 |
| NCT04669171 | Recruiting | Phase 1/Phase 2 | A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma | July 5, 2021 | September 30, 2029 |
| NCT04745559 | Recruiting | Phase 2 | Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy | February 18, 2021 | May 2025 |
| NCT04763083 | Recruiting | Phase 1 | First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies | May 14, 2021 | December 2025 |
| NCT04775745 | Recruiting | Phase 1 | Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. | July 19, 2021 | December 31, 2025 |
| NCT04792502 | Recruiting | Phase 2 | Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma | July 14, 2022 | August 1, 2027 |
| NCT04849351 | Recruiting | Phase 2 | Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma | April 14, 2021 | December 2024 |
| NCT04934930 | Recruiting | Phase 2 | Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status | January 29, 2020 | August 1, 2025 |
| NCT04998669 | Recruiting | Phase 2 | Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma | February 11, 2022 | August 2027 |
| NCT05006716 | Recruiting | Phase 1/Phase 2 | A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies | September 13, 2021 | March 31, 2028 |
| NCT05020392 | Recruiting | Phase 3 | Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma | September 14, 2021 | October 13, 2024 |
| NCT05058404 | Recruiting | Phase 3 | Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma | December 1, 2021 | July 2030 |
| NCT05255354 | Recruiting | Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy | June 1, 2022 | March 11, 2027 | |
| NCT05281809 | Recruiting | Phase 2 | Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia | April 19, 2022 | December 1, 2037 |
| NCT05284825 | Recruiting | N/A | A Phase II Trial of Intermediate Radiation Dose For Lymphoma | February 28, 2022 | January 1, 2025 |
| NCT05294731 | Recruiting | Phase 1/Phase 2 | Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader | March 24, 2022 | March 2027 |
| NCT05326308 | Recruiting | Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma | April 26, 2022 | April 2027 | |
| NCT05365659 | Recruiting | Phase 1 | IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas | September 5, 2023 | September 2027 |
| NCT05389293 | Recruiting | Phase 2 | A Study of Mosunetuzumab in People With Follicular Lymphoma | May 27, 2022 | December 2025 |
| NCT05410418 | Recruiting | Phase 2 | Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma | October 24, 2022 | October 31, 2031 |
| NCT05414162 | Recruiting | Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy | May 16, 2022 | December 2025 | |
| NCT05444322 | Recruiting | Early Phase 1 | A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma | July 5, 2022 | July 10, 2025 |
| NCT05458297 | Recruiting | Phase 2 | A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) | July 21, 2022 | April 26, 2027 |
| NCT05512390 | Recruiting | Phase 1 | A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL) | April 26, 2023 | February 7, 2027 |
| NCT05529524 | Recruiting | Signatures of Response and Resistance to Mosunetuzomab in Follicular Lymphomas (FL) | November 7, 2022 | September 1, 2024 | |
| NCT05541341 | Recruiting | Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies | November 24, 2023 | December 16, 2038 | |
| NCT05544019 | Recruiting | Phase 1 | Study of SGR-1505 in Mature B-Cell Neoplasms | April 10, 2023 | March 2026 |
| NCT05551936 | Recruiting | Phase 1/Phase 2 | A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma | January 26, 2023 | May 2025 |
| NCT05565417 | Recruiting | Phase 1/Phase 2 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | November 28, 2022 | April 2025 |
| NCT05602363 | Recruiting | Phase 1 | AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma | August 1, 2023 | September 2027 |
| NCT05618366 | Recruiting | Phase 1 | Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma | June 7, 2023 | December 2028 |
| NCT05621096 | Recruiting | Phase 1 | Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma | March 21, 2023 | July 2025 |
| NCT05653271 | Recruiting | Phase 1 | ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies | January 21, 2023 | September 2027 |
| NCT05665062 | Recruiting | Phase 1 | Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies | June 24, 2022 | November 2026 |
| NCT05783596 | Recruiting | Phase 2 | Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma | July 18, 2023 | January 8, 2029 |
| NCT05783609 | Recruiting | Phase 2 | Epcoritamab and Rituximab for First-line Follicular Lymphoma | June 21, 2023 | February 22, 2029 |
| NCT05805605 | Recruiting | Phase 2 | Allo HSCT Using RIC and PTCy for Hematological Diseases | May 1, 2023 | October 22, 2028 |
| NCT05816850 | Recruiting | Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial | September 19, 2023 | June 1, 2026 | |
| NCT05846763 | Recruiting | Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study | November 1, 2022 | May 31, 2028 | |
| NCT05899621 | Recruiting | A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL | June 1, 2023 | June 30, 2027 | |
| NCT05929222 | Recruiting | Phase 3 | Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi | December 14, 2023 | April 2031 |
| NCT05934838 | Recruiting | Phase 1 | A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas | October 4, 2023 | September 2031 |
| NCT05994235 | Recruiting | Phase 2 | Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma | November 1, 2023 | October 2033 |
| NCT06004167 | Recruiting | N/A | Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T) | January 14, 2024 | September 1, 2024 |
| NCT06014762 | Recruiting | Phase 1 | P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies | April 16, 2024 | March 2041 |
| NCT06022029 | Recruiting | Phase 1 | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | October 13, 2023 | August 29, 2026 |
| NCT06026319 | Recruiting | Phase 1 | CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma | October 26, 2023 | January 1, 2028 |
| NCT06043323 | Recruiting | Phase 2 | A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma | January 8, 2024 | September 1, 2028 |
| NCT06070961 | Recruiting | Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance | May 7, 2024 | May 2027 | |
| NCT06108232 | Recruiting | Phase 2 | Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma | March 15, 2024 | December 31, 2027 |
| NCT06112847 | Recruiting | Phase 2 | Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma | January 24, 2024 | October 14, 2025 |
| NCT06131801 | Recruiting | Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution | November 15, 2023 | December 1, 2027 | |
| NCT06151080 | Recruiting | Phase 2 | Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL | November 22, 2023 | December 31, 2026 |
| NCT06158386 | Recruiting | Phase 2 | Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma | November 22, 2023 | December 31, 2025 |
| NCT06284122 | Recruiting | Phase 3 | Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 | May 2024 | April 2034 |
| NCT06339255 | Recruiting | Italian Observational Study on CAR-T Therapy for Lymphoma | October 30, 2019 | December 31, 2029 | |
| NCT06340737 | Recruiting | Phase 1 | AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas | March 29, 2024 | April 2031 |
| NCT06350318 | Recruiting | Phase 2 | Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas | March 13, 2024 | March 2029 |
| NCT00475332 | Terminated | Phase 2 | Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar | September 2007 | April 2009 |
| NCT03178201 | Terminated | Phase 2 | TGR1202 in Relapsed and Refractory Follicular Lymphoma | August 20, 2017 | June 30, 2020 |
| NCT04844086 | Terminated | Phase 1 | RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies | March 2, 2021 | May 12, 2022 |
| NCT02991898 | Terminated | Phase 2 | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies | February 16, 2017 | June 20, 2019 |
| NCT02966730 | Terminated | Early Phase 1 | Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy | November 2016 | June 20, 2019 |
| NCT02877082 | Terminated | Phase 2 | Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients | September 2016 | July 2017 |
| NCT00942409 | Terminated | Phase 2 | Study of Repeat Intranodal Injections of Ad-ISF35 | June 2009 | July 2014 |
| NCT02793583 | Terminated | Phase 2/Phase 3 | Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma | May 25, 2016 | July 4, 2022 |
| NCT03436771 | Terminated | Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product | February 19, 2018 | July 20, 2018 | |
| NCT02700022 | Terminated | Phase 1 | A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas | October 2016 | August 18, 2017 |
| NCT00901927 | Terminated | Phase 2 | Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma | May 2009 | January 2016 |
| NCT02536300 | Terminated | Phase 3 | Dose Optimization Study of Idelalisib in Follicular Lymphoma | January 14, 2016 | September 27, 2022 |
| NCT03585725 | Terminated | Early Phase 1 | A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma | September 26, 2018 | July 22, 2020 |
| NCT02451111 | Terminated | Phase 2 | Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma | November 6, 2015 | July 15, 2023 |
| NCT00022971 | Terminated | Phase 1 | Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia | August 15, 2001 | March 17, 2017 |
| NCT02295722 | Terminated | Phase 1/Phase 2 | GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma | April 2015 | January 2023 |
| NCT03685344 | Terminated | Phase 1 | Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma | February 4, 2019 | October 27, 2020 |
| NCT02258555 | Terminated | Phase 1 | Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma | January 2015 | August 2015 |
| NCT02258529 | Terminated | Phase 2 | Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma | September 14, 2015 | May 3, 2016 |
| NCT03828448 | Terminated | Phase 2 | Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma | July 10, 2019 | May 31, 2022 |
| NCT02204982 | Terminated | Phase 3 | Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma | September 2014 | March 2017 |
| NCT00850499 | Terminated | Phase 2 | Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab | September 2009 | October 2011 |
| NCT02008006 | Terminated | Phase 2 | BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy and Transplantation (BENEFIT) | July 9, 2014 | July 12, 2018 |
| NCT03890289 | Terminated | Phase 2 | Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma | October 18, 2019 | May 10, 2023 |
| NCT03919175 | Terminated | Phase 2 | Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma | September 1, 2019 | May 5, 2024 |
| NCT01799889 | Terminated | Phase 2 | Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies | March 14, 2013 | January 30, 2020 |
| NCT01728207 | Terminated | Phase 1 | Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL | March 2013 | March 2017 |
| NCT01662102 | Terminated | Phase 3 | Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta) | December 11, 2012 | March 5, 2013 |
| NCT01500538 | Terminated | Phase 2 | A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL) | October 2012 | May 2014 |
| NCT01389076 | Terminated | Phase 2 | Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma | July 2011 | June 2016 |
| NCT01370694 | Terminated | Phase 1 | Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001) | August 19, 2011 | December 1, 2014 |
| NCT04176913 | Terminated | Phase 1 | Study of LUCAR-20S in Patients With R/R NHL | December 1, 2020 | December 9, 2021 |
| NCT00136591 | Terminated | Phase 2 | A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma | September 2005 | January 2010 |
| NCT01313611 | Terminated | Phase 2 | BRIEF Bendamustine and Rituximab In Elderly Follicular | February 2011 | December 2017 |
| NCT04342117 | Terminated | Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL | April 23, 2020 | December 31, 2020 | |
| NCT04358458 | Terminated | Phase 1/Phase 2 | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas | March 24, 2020 | July 28, 2023 |
| NCT05107856 | Terminated | Phase 1 | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies | March 22, 2022 | January 19, 2024 |
| NCT00479167 | Terminated | Phase 2 | A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma | May 2007 | September 2008 |
| NCT00096460 | Terminated | Phase 2/Phase 3 | Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202) | August 2004 | March 2009 |
| NCT05611853 | Terminated | Phase 1/Phase 2 | Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies | November 25, 2022 | December 25, 2023 |
| NCT04722601 | Terminated | Phase 1/Phase 2 | A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma | September 1, 2021 | March 31, 2023 |
| NCT01147393 | Terminated | Phase 1/Phase 2 | Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma | October 2010 | July 31, 2015 |
| NCT04762160 | Terminated | Phase 2 | SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma | December 15, 2020 | March 22, 2022 |
| NCT00772668 | Terminated | N/A | Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL | September 25, 2009 | February 2011 |
| NCT00384111 | Terminated | Phase 3 | Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL) | October 2006 | November 2008 |
| NCT01121757 | Terminated | Phase 2 | Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma | April 2010 | January 2016 |
| NCT03121677 | Terminated | Phase 1 | Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma | October 16, 2018 | August 7, 2023 |
| NCT03135262 | Terminated | Phase 1/Phase 2 | A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL) | June 15, 2017 | April 30, 2020 |
| NCT03151057 | Terminated | Phase 1 | Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies | July 31, 2018 | July 20, 2022 |
| NCT03037645 | Terminated | Phase 1/Phase 2 | Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers | April 28, 2017 | August 31, 2020 |
| NCT02423837 | Unknown status | Phase 3 | Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma | December 2013 | April 2021 |
| NCT00435955 | Unknown status | Phase 3 | Comparison of High-Dose Chemotherapy + Rituximab and CHOP + Rituximab in High-Risk Follicular Lymphoma | March 2000 | |
| NCT02819583 | Unknown status | Phase 1/Phase 2 | CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | October 2016 | September 2019 |
| NCT02791217 | Unknown status | Identification of Hematological Malignancies and Therapy Predication Using microRNAs as a Diagnostic Tool | June 2016 | June 2019 | |
| NCT03999697 | Unknown status | Phase 1 | A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies | December 1, 2018 | December 1, 2020 |
| NCT00907348 | Unknown status | Phase 2 | Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma | October 2007 | January 2012 |
| NCT00455416 | Unknown status | Phase 2 | Dietary Intervention in Follicular Lymphoma | April 2007 | December 2009 |
| NCT04379167 | Unknown status | Phase 2 | A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma | December 30, 2020 | December 30, 2022 |
| NCT04048395 | Unknown status | Clinical Outcomes of Early-progressed Follicular Lymphoma in Korea | July 8, 2019 | April 30, 2020 | |
| NCT00722930 | Unknown status | Phase 2 | Consolidation Treatment With Y90-Ibritumomab Tiuxetan After R-CHOP Induction in High Risk Patients According to Follicular Lymphoma International Prognostic Index (FLIPI) With Follicular Lymphoma | April 2008 | April 2013 |
| NCT04707079 | Unknown status | Phase 2 | A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma | December 18, 2019 | March 31, 2022 |
| NCT04154228 | Unknown status | N/A | Non-invasive Evaluation of Lymphoma Patients Based on Artificial Intelligence and PET/MRI | December 10, 2019 | December 10, 2021 |
| NCT04952974 | Unknown status | B-cell Chronic Lymphoid Malignancies Markers | June 14, 2021 | March 30, 2023 | |
| NCT03715309 | Unknown status | Phase 2 | R2 in the Treatment of Follicular Lymphoma | November 1, 2018 | November 1, 2020 |
| NCT00772655 | Unknown status | Phase 2 | Zevalin® First Line in Follicular Lymphoma | October 2007 | June 2015 |
| NCT03720457 | Unknown status | Phase 1 | Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma. | November 13, 2018 | October 2023 |
| NCT04842318 | Unknown status | Phase 4 | Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After BR or RCHOP or R2: a Multicenter Clinical Study | March 1, 2021 | March 1, 2024 |
| NCT04184414 | Unknown status | Early Phase 1 | The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies | January 9, 2018 | January 1, 2020 |
| NCT05003141 | Unknown status | Phase 1 | PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies | November 15, 2021 | January 2024 |
| NCT00530140 | Unknown status | Phase 2 | Idiotypic Vaccination for Follicular Lymphoma Patients | October 2007 | September 2022 |
| NCT01329354 | Unknown status | Phase 2 | Rituximab and Autologous Effector Lymphocytes in Non-Hodgkin Follicular Lymphoma in Response to First Line Chemotherapy | March 2011 | November 2019 |
| NCT03221348 | Unknown status | Phase 1 | A Phase I Study of Intravenous CHO-H01 in Patients With Refractory or Relapsed Follicular Lymphoma | March 2018 | November 2019 |
| NCT03234140 | Unknown status | Constitutional Genetics in Follicular Lymphoma | November 2017 | November 2019 | |
| NCT01303887 | Unknown status | Phase 3 | A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients | October 2009 | September 2016 |
| NCT02991638 | Unknown status | Phase 3 | Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers | November 1, 2016 | June 2021 |
| NCT00774826 | Unknown status | Phase 3 | Multicentric Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Patients With Stage II-IV Follicular Lymphoma | December 2005 | March 2014 |
| NCT01151358 | Unknown status | Evaluation of Patient and Lesion Specific Prognostic Factors for Standard Radioimmunotherapy | May 2008 | December 2011 | |
| NCT02892695 | Unknown status | Phase 1/Phase 2 | PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma | September 2016 | September 2019 |
| NCT02851589 | Unknown status | Phase 1/Phase 2 | Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | July 2016 | November 2019 |
| NCT04989621 | Unknown status | Phase 2 | Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL) | August 1, 2021 | August 2023 |
| NCT05867030 | Withdrawn | Phase 1 | Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma | July 28, 2023 | April 30, 2033 |
| NCT01163201 | Withdrawn | Phase 1/Phase 2 | T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies | January 2014 | January 2015 |
| NCT01180569 | Withdrawn | Phase 1/Phase 2 | Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular Lymphoma | August 2010 | May 2011 |
| NCT05176691 | Withdrawn | Phase 1 | HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL | February 15, 2022 | November 16, 2022 |
| NCT02576275 | Withdrawn | Phase 3 | A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) | December 2015 | November 2016 |
| NCT05934097 | Withdrawn | Phase 1 | FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma | December 2022 | May 2039 |
| NCT01460602 | Withdrawn | Phase 1/Phase 2 | Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma | May 2010 | October 2014 |
| NCT02623920 | Withdrawn | Phase 2 | Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | December 16, 2015 | May 17, 2017 |
| NCT04503538 | Withdrawn | N/A | Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity | December 2020 | November 2023 |
- Disase is a (Disease Ontology)
- DOID:707
- Cross Reference ID (Disease Ontology)
- GARD:2356
- Cross Reference ID (Disease Ontology)
- ICDO:9690/3
- Cross Reference ID (Disease Ontology)
- MESH:D008224
- Cross Reference ID (Disease Ontology)
- MIM:151430
- OrphaNumber from OrphaNet (Orphanet)
- 545
- ICD10 preferred id (Insert disease from ICD10)
- D0002237
- ICD10 class code (Insert disease from ICD10)
- C82